Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 1032-1038

  Goldstein, J ^a   Tran, B ^b,c,d   Ensor, J ^a   Gibbs, P ^b,c,d   Wong, H L ^b,c   Wong, S F ^b   Vilar, E ^a   Tie, J ^b,c,d   Broaddus, R ^a   Kopetz, S ^a   Desai, J ^b,c,d   Overman, M J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d Western Hospital   (Australia)

Author keywords

BRAF V600E mutation; chemotherapy; colorectal cancer; metastatectomy; microsatellite instability high; survival

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISSENSE MUTATION; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907814266     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu100     Document Type: Article

References (26)

1. Kim, H., Jen, J., Vogelstein, B., et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145 (1994), 148–156.
2. Koopman, M., Kortman, G.A., Mekenkamp, L., et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100 (2009), 266–273.
3. Lothe, R.A., Peltomaki, P., Meling, G.I., et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 53 (1993), 5849–5852.
4. Thibodeau, S.N., Bren, G., Schaid, D., Microsatellite instability in cancer of the proximal colon. Science 260 (1993), 816–819.
5. Sargent, D.J., Marsoni, S., Monges, G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28 (2010), 3219–3226.
6. Carethers, J.M., Chauhan, D.P., Fink, D., et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117 (1999), 123–131.
7. Gavin, P.G., Colangelo, L.H., Fumagalli, D., et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18 (2012), 6531–6541.
8. Bertagnolli, M.M., Niedzwiecki, D., Compton, C.C., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27 (2009), 1814–1821.
9. Sinicrope, F.A., Foster, N.R., Thibodeau, S.N., et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103 (2011), 863–875.
10. Tran, B., Kopetz, S., Tie, J., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117 (2011), 4623–4632.
11. Boland, C.R., Thibodeau, S.N., Hamilton, S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998), 5248–5257.
12. Golan, T., Urban, D., Berger, R., et al. Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location. Cancer 119 (2013), 3084–3091.
13. Liang, J.T., Huang, K.C., Lai, H.S., et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer 101 (2002), 519–525.
14. Brueckl, W.M., Moesch, C., Brabletz, T., et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res 23 (2003), 1773–1777.
15. des Guetz, G., Mariani, P., Cucherousset, J., et al. Microsatellite instability and sensitivity to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 27 (2007), 2715–2719.
16. Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27 (2009), 3677–3683.
17. Tejpar, S., Saridaki, Z., Delorenzi, M., et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst 103 (2011), 841–844.
18. Kanas, G.P., Taylor, A., Primrose, J.N., et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4 (2012), 283–301.
19. Schmoll, H.J., van Cutsem, E., Stein, A., et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23 (2012), 2479–2516.
20. Kim, S.T., Lee, J., Park, S.H., et al. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol 27 (2010), 1277–1285.
21. Muller, C.I., Schulmann, K., Reinacher-Schick, A., et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 23 (2008), 1033–1039.
22. Kim, J.E., Hong, Y.S., Ryu, M.H., et al. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Cancer Sci 102 (2011), 1706–1711.
23. Des Guetz, G., Uzzan, B., Nicolas, P., et al. Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Res 29 (2009), 1615–1620.
24. Vilar, E., Tabernero, J., Molecular dissection of microsatellite instable colorectal cancer. Cancer Discov 3 (2013), 502–511.
25. Samowitz, W.S., Sweeney, C., Herrick, J., et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65 (2005), 6063–6069.
26. Lochhead, P., Kuchiba, A., Imamura, Y., et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105 (2013), 1151–1156.